Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases

J Manag Care Pharm. 2012 Jan-Feb;18(1):74-5; author reply 75-6. doi: 10.18553/jmcp.2012.18.1.74.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antibodies, Monoclonal / economics*
  • Bone Density Conservation Agents / economics*
  • Bone Neoplasms / economics*
  • Cost-Benefit Analysis / economics*
  • Diphosphonates / economics*
  • Humans
  • Imidazoles / economics*
  • Male
  • Prostatic Neoplasms / economics*

Substances

  • Antibodies, Monoclonal
  • Bone Density Conservation Agents
  • Diphosphonates
  • Imidazoles